457 related articles for article (PubMed ID: 29681203)
1. The immunotherapy of Guillain-Barré syndrome.
Restrepo-Jiménez P; Rodríguez Y; González P; Chang C; Gershwin ME; Anaya JM
Expert Opin Biol Ther; 2018 Jun; 18(6):619-631. PubMed ID: 29681203
[TBL] [Abstract][Full Text] [Related]
2. A Novel Treatment Strategy for Severe Guillain-Barré Syndrome: Zipper Method.
Kesici S; Tanyıldız M; Yetimakman F; Bayrakci B
J Child Neurol; 2019 Apr; 34(5):277-283. PubMed ID: 30696330
[TBL] [Abstract][Full Text] [Related]
3. The role of immunotherapy in Guillain-Barré syndrome: understanding the mechanism of action.
Shahrizaila N; Yuki N
Expert Opin Pharmacother; 2011 Jul; 12(10):1551-60. PubMed ID: 21473704
[TBL] [Abstract][Full Text] [Related]
4. Guillain-Barré syndrome.
Hughes RA; Cornblath DR
Lancet; 2005 Nov; 366(9497):1653-66. PubMed ID: 16271648
[TBL] [Abstract][Full Text] [Related]
5. Treatment of acute immune-mediated neuropathies: Guillain-Barré syndrome and clinical variants.
Sederholm BH
Semin Neurol; 2010 Sep; 30(4):365-72. PubMed ID: 20941669
[TBL] [Abstract][Full Text] [Related]
6. Guillain-Barre syndrome in children.
Tabarki-Melaiki B
Neurosciences (Riyadh); 2011 Apr; 16(2):174-5. PubMed ID: 21427674
[No Abstract] [Full Text] [Related]
7. Guillain-Barré syndrome: epidemiology, pathophysiology and management.
Kuwabara S
Drugs; 2004; 64(6):597-610. PubMed ID: 15018590
[TBL] [Abstract][Full Text] [Related]
8. Guillain-Barré syndrome.
Willison HJ; Jacobs BC; van Doorn PA
Lancet; 2016 Aug; 388(10045):717-27. PubMed ID: 26948435
[TBL] [Abstract][Full Text] [Related]
9. Guillain-Barré syndrome.
Ansar V; Valadi N
Prim Care; 2015 Jun; 42(2):189-93. PubMed ID: 25979580
[TBL] [Abstract][Full Text] [Related]
10. The Guillain-Barré syndrome.
Fujimura H
Handb Clin Neurol; 2013; 115():383-402. PubMed ID: 23931791
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of Guillain-Barré syndrome.
Liu S; Dong C; Ubogu EE
Hum Vaccin Immunother; 2018; 14(11):2568-2579. PubMed ID: 29953326
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic strategies in the Guillain-Barré syndrome.
Kieseier BC; Hartung HP
Semin Neurol; 2003 Jun; 23(2):159-68. PubMed ID: 12894381
[TBL] [Abstract][Full Text] [Related]
13. [Plasmapheresis for Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy].
Odaka M
Nihon Rinsho; 2004 May; 62 Suppl 5():491-5. PubMed ID: 15197970
[No Abstract] [Full Text] [Related]
14. Therapeutic issues in Guillain-Barré syndrome.
Magy L; Frachet S
Expert Rev Neurother; 2023 Jun; 23(6):549-557. PubMed ID: 37151048
[TBL] [Abstract][Full Text] [Related]
15. Experience with Guillain-Barré syndrome in a neurological Intensive Care Unit.
González P; García X; Guerra A; Arango JC; Delgado H; Uribe CS; Sará J; López de Mesa JC; Hernández O
Neurologia; 2016; 31(6):389-94. PubMed ID: 25542501
[TBL] [Abstract][Full Text] [Related]
16. Plasmapheresis treatment in Guillain-Barré syndrome: potential benefit over intravenous immunoglobulin.
Buzzigoli SB; Genovesi M; Lambelet P; Logi C; Raffaelli S; Cattano D
Anaesth Intensive Care; 2010 Mar; 38(2):387-9. PubMed ID: 20369779
[TBL] [Abstract][Full Text] [Related]
17. Guillain-Barré syndrome: causes, immunopathogenic mechanisms and treatment.
Jasti AK; Selmi C; Sarmiento-Monroy JC; Vega DA; Anaya JM; Gershwin ME
Expert Rev Clin Immunol; 2016 Nov; 12(11):1175-1189. PubMed ID: 27292311
[TBL] [Abstract][Full Text] [Related]
18. Role of IV Immunoglobulin in Indian Children With Guillain-Barré Syndrome.
Kalita J; Kumar M; Misra UK
Pediatr Crit Care Med; 2019 Jul; 20(7):652-659. PubMed ID: 30985608
[TBL] [Abstract][Full Text] [Related]
19. Guillain-Barré syndrome and variants.
Dimachkie MM; Barohn RJ
Neurol Clin; 2013 May; 31(2):491-510. PubMed ID: 23642721
[TBL] [Abstract][Full Text] [Related]
20. Clinical features and real-world outcomes of Guillain-Barré syndrome in the Philippines.
I Espiritu A; Separa KJNJ; Milla FJC; Adiao KJB; Leochico CFD; Jamora RDG
Neurol Res; 2021 Dec; 43(12):995-1004. PubMed ID: 34229572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
